<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="forms of COVID-19 in the United States and Europe, while" exact="dexamethasone" post="is also recommended in specific situations and umifenovir, Î±-interferon,"/>
 <result pre="recommended in specific situations and umifenovir, Î±-interferon, lopinavir/ritonavir, ribavirin, and" exact="chloroquine" post="phosphate has been added to the Guidelines for the"/>
 <result pre="TMPRSS, transmembrane protease serine 2 (); mTORC1, mammalian target of" exact="rapamycin" post="complex 1 (); RLR, RIG-I-like receptors; ACE2, angiotensin converting"/>
 <result pre="RNA release in the presence of the mammalian target of" exact="rapamycin" post="complex 1 protein (rapamycin complex 1) (mTORC1) (4); RNA"/>
 <result pre="currently approached the antiviral role of endosomal-tropic agents such as" exact="hydroxychloroquine" post="sulfate or umifenovir (arbidol) (Yang and Shen, 2020). SARS-CoV-2"/>
 <result pre="complex enzymatic system, also controlled by the mammalian target of" exact="rapamycin" post="complex 1 (mTORC1). While it is still unclear how"/>
 <result pre="repurposing of previously known drugs such as cloroquine (Cq) and" exact="hydroxychloroquine" post="(Hq). Chloroquine phosphate, is an antimalarial drug which acts"/>
 <result pre="previously known drugs such as cloroquine (Cq) and hydroxychloroquine (Hq)." exact="Chloroquine" post="phosphate, is an antimalarial drug which acts through complex"/>
 <result pre="and nafmostat, approved by FDA for other non-viral indications. Additionally," exact="camostat" post="mesylate, a protease inhibitor approved by the FDA in"/>
 <result pre="ChiCTR2000029544 and ChiCTR2000029600) (Coomes and Haghbayan, 2020). Remdesivir is an" exact="adenosine" post="analogue which also controls mTORC1 signalling and has a"/>
 <result pre="has shown in vitro activity against SARS-CoV-2 in combination with" exact="chloroquine" post="(Wang M. et al., 2020) or in monotherapy, as"/>
 <result pre="nucleosidic analogues were recently disproved by clinical studies. These include" exact="ribavirin" post="(ChiCTR200002938) and protease inhibitors targeting PLpro and 3CLpro, such"/>
 <result pre="convincing clinical trials on this matter. Furthermore, the administration of" exact="azithromycin" post="also poses multiple cardiovascular risks (Ray et al., 2012)"/>
 <result pre="(Gautret et al., 2020) on the association between Hq and" exact="azithromycin" post="(NCR04321278) have been questioned by the International Society of"/>
 <result pre="2020). Biological treatment Study identifier number, locations IFN-beta, cholchicine, rivaroxaban," exact="aspirin" post="NCT04331899, Canada IFN-beta, remdesivir, chloroquine, hydroxychloroquine, lopinavir/ritonavir ISRCTN83971151 (Solidarity),"/>
 <result pre="NCT04315948 (DisCoVeRy), multi-centre (Europe) IFN-beta1a NCT04385095, UK IFN-beta1a, lopinavir, ritonavir," exact="hydroxychloroquine" post="NCT04350671 (IB1aIC), Iran IFN-beta1a, lopinavir, ritonavir, hydroxychloroquine NCT04350684 (UAIIC),"/>
 <result pre="IFN-beta1a, lopinavir, ritonavir, hydroxychloroquine NCT04350671 (IB1aIC), Iran IFN-beta1a, lopinavir, ritonavir," exact="hydroxychloroquine" post="NCT04350684 (UAIIC), Iran IFN-beta1b, hydroxychloroquine NCT04350281, Hong Kong IFN-alfa"/>
 <result pre="(IB1aIC), Iran IFN-beta1a, lopinavir, ritonavir, hydroxychloroquine NCT04350684 (UAIIC), Iran IFN-beta1b," exact="hydroxychloroquine" post="NCT04350281, Hong Kong IFN-alfa (aerosols), lopinavir/ritonavir, traditional Chinese medicines"/>
 <result pre="NCT04251871, China Recombinant human IFN-alpha1b ChiCTR2000030480, ChinaÂ IFN-alpha aerosol inhalation," exact="lopinavir" post="ChiCTR2000030535,Â China IFN-alpha, ribavirin, lopinavir/ritonavir ChiCTR2000029387, China IFN-alpha atomization,"/>
 <result pre="ChiCTR2000029756, China IFN-alpha aerosol/lopinavir/ritonavir ChiCTR2000031196, China IFN-alpha2b, tocilizumab, losartan, remdesivir," exact="hydroxychloroquine" post="+ combinations, methylprednisolone, convalescent serum NCT04349410 (FMTVDM), SUA Recombinant"/>
 <result pre="human IFN-alpha 1b ChiCTR2000030922, ChinaÂ Recombinant human IFN-alpha-1b (nasal drops)/thymosin" exact="alpha" post="1 NCT04320238, China PegIFN-Î±2b atomization, arbidol hydrochloride NCT04254874, China"/>
 <result pre="China PegIFN-Î±2b atomization, arbidol hydrochloride NCT04254874, China Long-acting IFN-alpha2a plus" exact="ribavirin" post="ChiCTR2000030922, China PegIFN-lambda-1a NCT04331899, SUA PegIFN-lambda1a NCT04354259 (ILIAD), Canada"/>
 <result pre="on their efficiency in viral or autoimune diseases, such as" exact="thalidomide" post="(NCT04273529, NCT04273581) or fingolimod (NCT04280588). Additionally, experimental data on"/>
 <result pre="viral or autoimune diseases, such as thalidomide (NCT04273529, NCT04273581) or" exact="fingolimod" post="(NCT04280588). Additionally, experimental data on the efficiency of these"/>
 <result pre="RECOVERY trial NCT04381936) have reported a positive effect of intravenous" exact="dexamethasone" post="administration in the treatment of COVID-19. The study showed"/>
 <result pre="study showed that a 10-day treatment with low doses of" exact="dexamethasone" post="(6 mg/day) reduced the mortality in patients who required"/>
 <result pre="MSC (called PLX-PAD) NCT04389450 (140), SUA MSC in combination with" exact="ruxolitinib" post="ChiCTR2000029580, ChinaÂ Allogeneic human dental pulp derived-stem cells NCT04336254,"/>
 <result pre="antiCD147 receptor) (Wang K. et al., 2020) NCT04275245 Clathrin-mediated endocytosis" exact="Hydroxychloroquine" post="(Hq) sulphate (Picot et al., 1993; Jang et al.,"/>
 <result pre="1993; Jang et al., 2006; Bender et al., 2020) and" exact="Chloroquine" post="phosphate (Savarino et al., 2003; Vincent et al., 2005)*multiple"/>
 <result pre="(Hung et al., 2020)Controversial results (Gandhi, 2020) See Table 1" exact="Ruxolitinib" post="(anti-Janus kinase inhibitor) (Gaspari et al., 2020; Yeleswaram et"/>
 <result pre="cytokines, Th2 response, regeneration of damaged cell See Table 2" exact="Thalidomide" post="NCT04273529, NCT04273581 Fingolimod NCT04280588 Neutralizing antibodies Convalescent plasma (Rogers"/>
 <result pre="C.BritoM.et al. (2020). Effect of High vs Low Doses of" exact="Chloroquine" post="Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe"/>
 <result pre="Therapy for COVID-19. NEJM J. Watch2020. 10.1056/NEJM-JW.NA51564 GaspariV.ZengariniC.GrecoS.VangeliV.MastroianniA.Side effects of" exact="ruxolitinib" post="in patients with SARS-CoV-2 infection: Two case reports. Int."/>
 <result pre="J. Antimicrob. Agents56 (2), 106023. 10.1016/J.IJANTIMICAG.2020.106023 GautretP.LagierJ.-C.ParolaP.HoangV. T.MeddebL.MailheM.et al. (2020)." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
 <result pre="Agents56 (2), 106023. 10.1016/J.IJANTIMICAG.2020.106023 GautretP.LagierJ.-C.ParolaP.HoangV. T.MeddebL.MailheM.et al. (2020). Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
 <result pre="Agents56 (1), 105949. 10.1016/j.ijantimicag.2020.10594932205204 GelerisJ.SunY.PlattJ.ZuckerJ.BaldwinM.HripcsakG.et al. (2020). Observational Study of" exact="Hydroxychloroquine" post="in Hospitalized Patients with Covid-19. N. Engl. J. Med.382"/>
 <result pre="W.-H.ChuM.-Y.et al. (2020). Triple combination of interferon beta-1b, lopinavir-ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
 <result pre="Chemother.26 (6), 625â€&quot;632. 10.1016/j.jiac.2020.04.00732362440 JangC. H.ChoiJ. H.ByunM. S.JueD. M. (2006)." exact="Chloroquine" post="inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated"/>
 <result pre="(6), e46â€&quot;e47. 10.1016/S2213-2600(20)30216-232353251 JuurlinkD. N. (2020). Safety considerations with chloroquine," exact="hydroxychloroquine" post="and azithromycin in the management of SARS-CoV-2 infection. CMAJ192"/>
 <result pre="10.1016/S2213-2600(20)30216-232353251 JuurlinkD. N. (2020). Safety considerations with chloroquine, hydroxychloroquine and" exact="azithromycin" post="in the management of SARS-CoV-2 infection. CMAJ192 (17), E4540â€&quot;E453."/>
 <result pre="JAMA323 (8), 725. 10.1001/jama.2019.22525 RayW. A.MurrayK. T.HallK.ArbogastP. G.SteinC. M. (2012)." exact="Azithromycin" post="and the Risk of Cardiovascular Death. N. Engl. J."/>
 <result pre="COVID-19. Antiviral Res.178, 104791. 10.1016/j.antiviral.2020.10479132275914 SavarinoA.BoelaertJ. R.CassoneA.MajoriG.CaudaR. (2003). Effects of" exact="chloroquine" post="on viral infections: an old drug against todayâ€™s diseases?"/>
 <result pre="Infect. Dis.3 (11), 722â€&quot;727. 10.1016/S1473-3099(03)00806-514592603 ShamshirianA.HessamiA.HeydariK.Alizadeh-NavaeiR.EbrahimzadehM. A.YIPG. W.et al. (2020)." exact="Hydroxychloroquine" post="Versus COVID-19: A Periodic Systematic Review and Meta-Analysis. medRxiv.2020.04.14.20065276."/>
 <result pre="(7), 2657. 10.3390/ijms21072657 VincentM. J.BergeronE.BenjannetS.EricksonB. R.RollinP. E.KsiazekT. G.et al. (2005)." exact="Chloroquine" post="is a potent inhibitor of SARS coronavirus infection and"/>
 <result pre="Nat. Commun.11 (1), 2251. 10.1038/s41467-020-16256-y32366817 WangM.CaoR.ZhangL.YangX.LiuJ.XuM.et al. (2020). Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="Acad. Sci.117 (20), 10970â€&quot;10975. 10.1073/PNAS.200561511732350134 YamamotoM.MatsuyamaS.LiX.TakedaM.KawaguchiY.InoueJ.-I.et al. (2016). Identification of" exact="Nafamostat" post="as a Potent Inhibitor of Middle East Respiratory Syndrome"/>
 <result pre="Vitro Antiviral Activity and Projection of Optimized Dosing Design of" exact="Hydroxychloroquine" post="for the Treatment of Severe Acute Respiratory Syndrome Coronavirus"/>
 <result pre="732â€&quot;739. 10.1093/cid/ciaa23732150618 YeleswaramS.SmithP.BurnT.CovingtonM.JuvekarA.LiY.et al. (2020). Inhibition of cytokine signaling by" exact="ruxolitinib" post="and implications for COVID-19 treatment. Clin. Immunol.218, 108517. 10.1016/j.clim.2020.10851732585295"/>
</results>
